An van Es-Johansson
Director/Board Member chez SAVARA INC.
Fortune : 115 152 $ au 31/03/2024
Profil
An van Es-Johansson is currently serving as an Independent Director at Plus Therapeutics, Inc., Lumos Pharma Sub, Inc., Savara, Inc., Lumos Pharma, Inc., and as a Member-Supervisory Board at Agendia, Inc. He is also a Director at van Es Consulting AB.
In the past, he served as an Independent Director at BioInvent International AB and Medivir AB, and as VP & Head-EMENAR Medical Affairs at Swedish Orphan Biovitrum AB.
He was also the Chief Medical Officer & Head-Development at AlzeCure Pharma AB.
Dr. van Es-Johansson holds a doctorate degree from Erasmus University Rotterdam.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SAVARA, INC.
0,02% | 14/12/2023 | 22 500 ( 0,02% ) | 112 050 $ | 31/03/2024 |
LUMOS PHARMA, INC.
0,01% | 10/05/2023 | 1 100 ( 0,01% ) | 3 102 $ | 31/03/2024 |
PLUS THERAPEUTICS, INC.
-.--% | 22/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de An van Es-Johansson
| Sociétés | Poste | Début |
|---|---|---|
| SAVARA INC. | Director/Board Member | 03/12/2019 |
| PLUS THERAPEUTICS, INC. | Director/Board Member | 01/01/2020 |
| LUMOS PHARMA, INC. | Director/Board Member | 13/02/2021 |
| van Es Consulting AB | Director/Board Member | - |
Agendia, Inc.
 Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Director/Board Member | - |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Director/Board Member | 01/07/2019 |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Director/Board Member | 01/02/2021 |
Anciens postes connus de An van Es-Johansson
| Sociétés | Poste | Fin |
|---|---|---|
| MEDIVIR AB | Director/Board Member | 05/05/2022 |
| ALZECURE PHARMA AB | Chief Tech/Sci/R&D Officer | 01/03/2021 |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de An van Es-Johansson
| Erasmus University Rotterdam | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 8 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| MEDIVIR AB | Health Technology |
| PLUS THERAPEUTICS, INC. | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| IRLAB THERAPEUTICS AB | Health Technology |
| SAVARA INC. | Health Technology |
| ALZECURE PHARMA AB | Health Technology |
| LUMOS PHARMA, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Health Technology |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Health Services |
| van Es Consulting AB |
